This review summarizes the evidence linking specific genetic polymorphisms to aspirin resistance and subsequent cardiovascular events.
Answers are grounded in this paper and cite their sources.
Genetic testing for aspirin resistance should not guide therapy; review leaves open clinical utility pending prospective trials.
The review presents the current literature evidence on the most likely genetic polymorphisms of aspirin resistance, such as polymorphisms of cyclooxygenase, glycoproteins GP Ib/IIIa, GP Ibα, GP VI, and adenosine diphosphate receptors P2Y1 and P2Y12. The authors discuss the prevalence of these polymorphisms in laboratory and clinical aspirin resistance, as well as their association with the risk of cardiovascular events during aspirin treatment.
No takes yet. Share an insight, caveat, or question.
Grinshtein et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: